Neural Therapeutics Income Statement

Financials in millions CAD. Fiscal year is August - July.

Millions CAD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jan '26 Jan 31, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022
Selling, General & Admin	0.45	0.49	0.37	0.8	0.7
Research & Development	0.03	0.08	0.29	0.4	0.04
Operating Expenses	0.89	0.97	0.65	1.2	0.74
Operating Income	-0.89	-0.97	-0.65	-1.2	-0.74
Currency Exchange Gain (Loss)	-0	0	0	-0	0
Other Non Operating Income (Expenses)	-0.14	-0.09	-0.01	-0	-0
EBT Excluding Unusual Items	-1.3	-1.06	-0.67	-1.21	-0.74
Other Unusual Items	0.03	0.03	-	0.14	-1.08
Pretax Income	-1.26	-1.03	-0.67	-1.08	-1.82
Net Income	-1.26	-1.03	-0.67	-1.08	-1.82
Net Income to Common	-1.26	-1.03	-0.67	-1.08	-1.82
Shares Outstanding (Basic)	124	75	63	40	37
Shares Outstanding (Diluted)	124	75	63	40	37
Shares Change (YoY)	87.15%	19.37%	58.39%	7.98%	-
EPS (Basic)	-0.01	-0.01	-0.01	-0.03	-0.05
EPS (Diluted)	-0.01	-0.01	-0.01	-0.03	-0.05
EBIT	-0.89	-0.97	-0.65	-1.2	-0.74

Source: S&P Global Market Intelligence. Standard template. Financial Sources.